Activity of novel antifungal compound APX001A against a large collection of Candida auris
- PMID: 30085167
- DOI: 10.1093/jac/dky302
Activity of novel antifungal compound APX001A against a large collection of Candida auris
Abstract
Background: APX001A is an antifungal agent that targets a novel pathway-glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi.
Objectives: To determine the activity of APX001A against the emerging fungal pathogen Candida auris.
Methods: APX001A was tested by broth microdilution against 100 geographically distinct isolates of C. auris.
Results: APX001A showed activity against all isolates, including some that were resistant to one or more antifungals, with MIC50 and MIC90 of 0.002 and 0.008 mg/L, respectively.
Conclusions: These findings suggest that APX001A shows encouraging activity against the emerging fungal pathogen C. auris.
Similar articles
-
In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00840-19. doi: 10.1128/AAC.00840-19. Print 2019 Aug. Antimicrob Agents Chemother. 2019. PMID: 31182527 Free PMC article.
-
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01225-18. doi: 10.1128/AAC.01225-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30104264 Free PMC article.
-
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris.Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02319-17. doi: 10.1128/AAC.02319-17. Print 2018 Mar. Antimicrob Agents Chemother. 2018. PMID: 29311065 Free PMC article.
-
Candida auris: An emerging multidrug-resistant pathogen.Int J Infect Dis. 2017 Oct;63:95-98. doi: 10.1016/j.ijid.2017.08.017. Epub 2017 Sep 6. Int J Infect Dis. 2017. PMID: 28888662 Review.
-
Candida auris: The recent emergence of a multidrug-resistant fungal pathogen.Med Mycol. 2019 Jan 1;57(1):1-12. doi: 10.1093/mmy/myy054. Med Mycol. 2019. PMID: 30085270 Review.
Cited by
-
Antifungal therapy of Candida biofilms: Past, present and future.Biofilm. 2023 Apr 23;5:100126. doi: 10.1016/j.bioflm.2023.100126. eCollection 2023 Dec. Biofilm. 2023. PMID: 37193227 Free PMC article.
-
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review.J Fungi (Basel). 2022 Oct 28;8(11):1144. doi: 10.3390/jof8111144. J Fungi (Basel). 2022. PMID: 36354911 Free PMC article. Review.
-
Advancements and challenges in antifungal therapeutic development.Clin Microbiol Rev. 2024 Mar 14;37(1):e0014223. doi: 10.1128/cmr.00142-23. Epub 2024 Jan 31. Clin Microbiol Rev. 2024. PMID: 38294218 Free PMC article. Review.
-
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species.Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01387-19. doi: 10.1128/AAC.01387-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31611349 Free PMC article.
-
Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections.J Fungi (Basel). 2020 Oct 22;6(4):239. doi: 10.3390/jof6040239. J Fungi (Basel). 2020. PMID: 33105672 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
